Log In
Print this Print this

BACE1 inhibitor

  Manage Alerts
Collapse Summary General Information
Company CoMentis Inc.
DescriptionBeta-site APP-cleaving enzyme 1 (BACE 1) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerAstellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today